Resources - Cytotheryx, Inc.

More About Cytotheryx

Transformative research and therapeutics begin with a strong foundation. The following resources share more about our foundational science guiding our platform technology.

EVENTS SPACE

Upcoming Events

We’re excited to share more about our work with the world and to develop important relationships across the industry, so we regularly attend industry events. Join us at any of the following events to learn more about our work and future opportunities for partnering together for your drug discovery, research and therapeutic development needs.

11.10-14.2023 | The Liver Meeting

As the premier conference in the liver disease research space, The Liver Meeting brings together leaders for networking, scientific conversations and symposia, and educational workshops. We will be exhibiting at the Liver Meeting Booth C2415 in November and are excited to be contributing to the ongoing excitement around cutting-edge liver disease research. Learn More »

1.8-11.2024 | 2023 Cell & Gene Meeting on the Mesa

We will attend the annual JPM week. We’re excited to attend to have meaningful conversations and build relationships with other industry leaders and investors.

The Liver Meeting

November 10-14, 2023

As the premier conference in the liver disease research space, The Liver Meeting brings together leaders for networking, scientific conversations and symposia, and educational workshops. We will be exhibiting at the Liver Meeting Booth C2415 in November and are excited to be contributing to the ongoing excitement around cutting-edge liver disease research.

JPM Week

January 8-11, 2024

We will attend the annual JPM week. We’re excited to attend to have meaningful conversations and build relationships with other industry leaders and investors.

Learn More from Cytotheryx

Explore Cytotheryx’ latest innovations and advancements in biomedical research and technology. Read our latest articles, news coverage, and press releases for more information on how our platform technology is revolutionizing human health and how our team is engaging with the wider community.

Financing Update

Cytotheryx’s Series A financing, alongside strategic debt funding, will advance its cell therapy programs toward clinical development and support GMP manufacturing scale-up. Cytotheryx has opened

Introducing Cytocine™: Primary Porcine Hepatocytes

Cytocine™ Cryopreserved Primary Porcine Hepatocytes offer a valuable alternative to human hepatocytes for preclinical research applications. With high viability, plateability, metabolic functionality, and scalability, Cytocine™ hepatocytes provide a reliable and cost-effective solution for researchers who need a consistent supply of cells for their experiments. Dive into our latest White Paper to learn more about this new source of high-quality liver cells to support biomedical research.

Cytotheryx to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

ROCHESTER, Minnesota, Oct. 11, 2024 – Cytotheryx, Inc., a privately held company focused on the development of a consistent, high-quality source of human hepatocytes (liver

FAQ

Get answers to our most frequently asked questions here and visit our FAQ page for more questions and answers.

What are primary human hepatocytes?

Hepatocytes are a type of cell that makes up the majority of the liver. These cells are responsible for liver functions such as metabolism of carbohydrates and lipids, detoxification, and the storage and synthesis of proteins. Primary hepatocytes are cells derived directly from the liver tissue, as opposed to hepatocytes that are derived from other cells, like stem cells. Primary human hepatocytes are the ideal cell types for a variety of research and clinical applications.

How are Cytotheryx’ primary human hepatocytes different from what is currently offered today?

Currently, the supply of primary human hepatocytes is limited because individual cells are derived from whole livers from organ donors. When these cells become available, they are often unpredictable, inconsistent, and costly, and the number of cells is limited by the size and health of the donated liver. All of these factors can inhibit research and development over time. Cytotheryx’ primary human hepatocytes are more consistent, more readily available, and of a higher quality than alternatives. With our bio-incubators, we are able to develop and replicate dependable, high-quality cells over time, for more consistent sourcing, utilization and results.

How are primary human hepatocytes sourced?

Human hepatocytes can only grow and replicate within a living system, making them challenging to source for research and clinical applications. If human hepatocytes are required for scientific development, such as drug discovery or disease research, they must currently be sourced from whole livers or resected liver tissue from organ donors. The current model of sourcing leads to inconsistencies in quality across cells, as well as a limited quantity of available cells. Cytotheryx’ model will increase consistency and availability of primary human hepatocytes for drug discovery, research, therapeutics development, and beyond.

What are primary human hepatocytes used for?

Human hepatocytes, and specifically primary human hepatocytes, are the cells used most commonly in toxicity, metabolism, and drug interaction research. Primary human hepatocytes are considered the “gold standard” for a variety of research and clinical applications, including safety and toxicity testing during drug development and the advancement of disease-specific research. As Cytotheryx makes this valuable resource more available, additional applications in both research and therapeutics will become possible.

Why is a better supply of hepatocytes needed for therapeutic applications?

Over 4.5 million people in the U.S. have been diagnosed with liver disease, and treatment options for liver disease are limited. While recommended lifestyle changes and therapeutics do exist as treatment options, the only current curative option as liver disease progresses into liver failure is organ transplantation. Hepatocytes have been shown to be valuable in therapeutic applications, such as the treatment of liver failure, through an external liver assist device or through direct cellular therapy. However, a clinically safe and consistent source of those cells does not exist. This unmet need limits the potential of therapeutic applications significantly. With a clinically safe, consistent, and high-quality source of liver cells, additional therapeutics could be developed and advanced for the treatment of liver disease, liver failure and rare diseases. Cytotheryx is prepared to meet that critical need.